Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Ibeas P, Cantos B, Provencio M.

Published Date November 2011 Volume 2011:1 Pages 19—22


Published 8 November 2011

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Activities of methionine-γ-lyase in the acidophilic archaeon “Ferroplasma acidarmanus” strain fer1

Khan MA, López-Muñoz MM, Kaspar CW, Hung KF

Research and Reports in Biology 2013, 4:11-22

Published Date: 4 April 2013

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

Smaldone MC, Chen DY, Yu JQ, Plimack ER

Biologics: Targets and Therapy 2012, 6:395-407

Published Date: 19 November 2012

Analysis of indoor air pollutants checklist using environmetric technique for health risk assessment of sick building complaint in nonindustrial workplace

Syazwan AI, Mohd Rafee B, Juahir H, Azman AZ, Nizar AM, Izwyn Z, Syahidatussyakirah K, Muhaimin AA, Syafiq Yunos MA, Anita AR, Muhamad Hanafiah J, Shaharuddin MS, Mohd Ibthisham A, Mohd Hasmadi I, Mohamad Azhar MN, Azizan HS, Zulfadhli I, Othman J, Rozalini M, Kamarul FT

Drug, Healthcare and Patient Safety 2012, 4:107-126

Published Date: 21 September 2012

Reduced intensity treatment in early-stage Hodgkin’s lymphoma

Prodduturi P, Armitage JO

Blood and Lymphatic Cancer: Targets and Therapy 2011, 1:23-31

Published Date: 25 November 2011

Hair dye-incorporated poly-γ-glutamic acid/glycol chitosan nanoparticles based on ion-complex formation

Lee HY, Jeong YI, Choi KC

International Journal of Nanomedicine 2011, 6:2879-2888

Published Date: 17 November 2011

Thermal and ultrasonic influence in the formation of nanometer scale hydroxyapatite bio-ceramic

Poinern GE, Brundavanam RK, Le XT, Djordjevic S, Prokic M, Fawcett D

International Journal of Nanomedicine 2011, 6:2083-2095

Published Date: 23 September 2011

Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells

Edmond Kahn, Mauhamad Baarine, Sophie Pelloux, et al

International Journal of Nanomedicine 2010, 5:185-195

Published Date: 16 March 2010